Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART® molecule for the treatment of hematological malignancies

被引：3

作者：

Moore, P. ^{[1
]}

Chichili, G. R. ^{[1
]}

Huang, L. ^{[1
]}

Li, H. ^{[1
]}

Burke, S. ^{[1
]}

Chen, F. ^{[2
]}

He, L. ^{[1
]}

Tang, Q. ^{[1
]}

Jin, L. ^{[1
]}

Gorlatov, S. ^{[1
]}

Ciccarone, V. ^{[1
]}

Koenig, S. ^{[1
]}

Shannon, M. ^{[1
]}

Alderson, R. ^{[1
]}

Johnson, S. ^{[1
]}

Bonvini, E. ^{[1
]}

机构：

[1] MacroGenics, Rockville, MD USA

[2] MacroGenics, San Francisco, CA USA

来源：

EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷

关键词：

D O I：

10.1016/S0959-8049(14)70264-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

138

引用

页码：48 / 48

页数：1

共 50 条

[31] CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies
Lisle, Jessica
Krishnamurthy, Sushma
Halfond, Amanda
Pechilis, Lisa
Manalo, Nate
Chng, Melissa
Gjeci, Brikena
Angelini, Gabriella
Norman, Fulton
Lourenco, Caitlin
Mager, Hannah
Etchin, Julia
Keschner, Yonina
Silva, Mariana
Mattson, Bethany
Barreyro, Laura
Guttke, Christina
Lydeard, John
Scherer, Julian
Lin, Michelle I.
Chakraborty, Tirtha
BLOOD, 2023, 142
[32] Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primates
Comeau, Michael R.
Miller, Robert E.
Bannink, Jeannette
Johnson, Starrla
Bader, Robert
Gottschalk, Rebecca
Misher, Lynda
Mitchell, Danielle
Parr, Lara
DeFrancesco, Melissa
Bienvenue, David
McMahan, Catherine J.
Hoyos, Gabriela H.
Gross, Jane A.
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[33] Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in a Primary Refractory t-AML Patient
Godwin, John
Ballesteros-Merino, Carmen
Bifulco, Carlo B.
Lelievre, Helene
Wigginton, Jon
Davidson-Moncada, Jan K.
Fox, Bernard
BLOOD, 2018, 132
[34] IGM-2644, a CD38xCD3 bispecific IgM T cell engager, shows enhanced anti-tumor activity compared to daratumumab in preclinical models of multiple myeloma
Hart, Kevin C.
Santos, Daniel
Li, Keyu
Yun, Rui
Chai, Min
Kabai, Andras
Li, Gene
Yakkundi, Poonam
Funke, Roel P.
Guan, Yinghui
Manley, Thomas
Liu, Liqin
Sinclair, Angus M.
Candia, Albert F.
Keyt, Bruce
Kotturi, Maya F.
CANCER RESEARCH, 2024, 84 (06)
[35] Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies
Hiemstra, Ida H.
Engelberts, Patrick J.
de Jong, Bart
Schuurhuis, Danita H.
Salcedo, Theodora W.
Verploegen, Sandra
van der Zee, Marten
Gerritsen, Arnout F.
Losic, Nedjad
Horbach, Sjeng
Oliveri, Roberto
van Bueren, Jeroen J. Lammerts
Usher, Pernille Autzen
Schuurman, Janine
Parren, Paul W. H. I.
Breij, Esther C. W.
BLOOD, 2018, 132
[36] MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment
LaMotte-Mohs, Ross
Shah, Kalpana
Smith, Doug
Gorlatov, Sergey
Ciccarone, Valentina
Tamura, James
Li, Hua
Rillema, Jill
Licea, Monica
He, Leilei
Vasanwala, Farha
Chen, Wei
Yao, Xiao-Tao
Chen, Francine
Brown, Jennifer
Nordstrom, Jeffrey
Koenig, Scott
Bonvini, Ezio
Johnson, Syd
Moore, Paul
CANCER RESEARCH, 2016, 76
[37] Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Root, Adam R.
Cao, Wei
Li, Bilian
LaPan, Peter
Meade, Caryl
Sanford, Jocelyn
Jin, Macy
O'Sullivan, Cliona
Cummins, Emma
Lambert, Matthew
Sheehan, Alfredo D.
Ma, Weijun
Gatto, Scott
Kerns, Kelvin
Lam, Khetemenee
D'Antona, Aaron M.
Zhu, Lily
Brady, William A.
Benard, Susan
King, Amy
He, Tao
Racie, Lisa
Arai, Maya
Barrett, Dianah
Stochaj, Wayne
LaVallie, Edward R.
Apgar, James R.
Svenson, Kristine
Mosyak, Lidia
Yang, Yinhua
Chichili, Gurunadh R.
Liu, Liqin
Li, Hua
Burke, Steve
Johnson, Syd
Alderson, Ralph
Finlay, William J. J.
Lin, Laura
Olland, Stephane
Somers, William
Bonvini, Ezio
Gerber, Hans-Peter
May, Chad
Moore, Paul A.
Tchistiakova, Lioudmila
Bloom, Laird
ANTIBODIES, 2016, 5 (01)
[38] First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.
Brownstein, Carrie M.
Adriaens, Lieve
Bannerji, Rajat
Chavez, Julio C.
Levy, Ronald
Ansell, Stephen Maxted
Advani, Ranjana H.
Patel, Snehal
Kostic, Ana
Trail, Pamela
Lowy, Israel
Kohrt, Holbrook Edwin
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[39] CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Martens, Anne W. J.
Janssen, Susanne R.
Derks, Ingrid A. M.
Adams, Homer C., III
Izhak, Liat
van Kampen, Roel
Tonino, Sanne H.
Eldering, Eric
van der Windt, Gerritje J. W.
Kater, Arnon P.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
[40] Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
Watts, Justin
Lin, Tara L.
Mims, Alice
Patel, Prapti
Lee, Cynthia
Shahidzadeh, Anoush
Shami, Paul
Cull, Elizabeth
Cogle, Christopher R.
Wang, Eunice
Uckun, Fatih M.
FRONTIERS IN ONCOLOGY, 2022, 11

← 1 2 3 4 5 →